A sudden development in the genetic-editing sector, another wild week for Nvidia, and much more.
A bold Nvidia investment that didn’t grab headlines, a paradigm shift for commodity markets, and more.
Fed cut odds shift, EchoStar–SpaceX deal, Nike/Dick’s calls, BofA downgrade, pharma pressure, streaming shakeup.
